<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612001</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000585166</org_study_id>
    <secondary_id>R01CA112358</secondary_id>
    <secondary_id>UCLA-06-01-052</secondary_id>
    <nct_id>NCT00612001</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Malignant Glioma</brief_title>
  <official_title>Phase I Study of Glioma-Associated Antigen (GAA) Peptide-pulsed Dendritic Cell Vaccination in Malignant Glioma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides and a person's dendritic cells may help the body build&#xD;
      an effective immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients with malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of autologous dendritic&#xD;
           cells pulsed with synthetic glioma-associated antigen (GAA) peptides in patients with&#xD;
           malignant gliomas.&#xD;
&#xD;
        -  Determine survival, tumor progression, and cellular immune response in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo leukapheresis for the collection of peripheral blood mononuclear&#xD;
      cells (PBMC). Autologous dendritic cells (DC) are prepared from autologous PBMC exposed to&#xD;
      sargramostim (GM-CSF) and interleukin-4 (IL-4), matured with a cytokine cocktail, and pulsed&#xD;
      with synthetic glioma-associated antigen (GAA) peptides. Cohorts of patients receive&#xD;
      escalating doses of GAA peptide-pulsed autologous dendritic cell vaccine until the maximum&#xD;
      tolerated dose is determined.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor progression</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>dendritic cell vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine</intervention_name>
    <arm_group_label>dendritic cell vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following malignant gliomas:&#xD;
&#xD;
          -  Anaplastic astrocytoma&#xD;
&#xD;
          -  Glioblastoma multiforme&#xD;
&#xD;
          -  Oligodendroglioma&#xD;
&#xD;
          -  Oligoastrocytoma&#xD;
&#xD;
          -  WHO grade III or IV disease&#xD;
&#xD;
          -  Newly diagnosed or recurrent disease&#xD;
&#xD;
          -  Bidimensionally measurable disease by contrast-enhancing MRI&#xD;
&#xD;
          -  Surgically accessible tumor for which resection is indicated&#xD;
&#xD;
          -  Previously treated with or planning to undergo treatment with conventional external&#xD;
             beam radiotherapy&#xD;
&#xD;
          -  HLA-A*201 positive&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  BUN ≤ 1.5 times normal OR creatinine ≤ 1.5 times normal&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Syphilis serology negative&#xD;
&#xD;
          -  Afebrile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  autoimmune disease that may be exacerbated by immunotherapy, including any of the&#xD;
             following:&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  Vasculitis&#xD;
&#xD;
          -  Polymyositis-dermatomyositis&#xD;
&#xD;
          -  Scleroderma&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Juvenile-onset insulin-dependent diabetes&#xD;
&#xD;
          -  allergy to study agents&#xD;
&#xD;
          -  underlying condition that would contraindicate study therapy&#xD;
&#xD;
          -  concurrent severe or unstable medical condition that would preclude giving informed&#xD;
             consent&#xD;
&#xD;
          -  psychiatric condition that would preclude study participation or giving informed&#xD;
             consent&#xD;
&#xD;
          -  other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  prior chemotherapy (6 weeks for nitrosoureas) within last 4 weeks of starting&#xD;
             treatment&#xD;
&#xD;
          -  concurrent corticosteroids within 2 weeks prior to treatment&#xD;
&#xD;
          -  radiotherapy within 2 weeks prior to treatment&#xD;
&#xD;
          -  systemic antibiotics within 72 hours prior to treatment&#xD;
&#xD;
          -  prior organ allograft&#xD;
&#xD;
          -  antihistamine therapy within 5 days before or after administration of study vaccine&#xD;
&#xD;
          -  chemotherapy during and for 4 weeks after administration of study vaccine&#xD;
&#xD;
          -  adjuvant therapy during and for 4 weeks after administration of study vaccine&#xD;
&#xD;
          -  other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda M. Liau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult mixed glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

